CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
73 hedge funds and large institutions have $122M invested in CASI Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 30 increasing their positions, 17 reducing their positions, and 6 closing their positions.
105% more capital invested
Capital invested by funds: $59.6M → $122M (+$62.5M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
76% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 17
9% more funds holding
Funds holding: 67 → 73 (+6)
0.15% more ownership
Funds ownership: 3.2% → 3.34% (+0.15%)
Top Buyers
| 1 |
CCM
Consonance Capital Management
New York
|
+$2.21M |
| 2 |
WSCM
Wellington Shields Capital Management
New York
|
+$1.41M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$889K |
| 4 |
WSC
Wellington Shields & Co
New York
|
+$724K |
| 5 |
BlackRock
New York
|
+$693K |
Top Sellers
| 1 |
Renaissance Technologies
New York
|
-$1.15M |
| 2 |
Millennium Management
New York
|
-$1.11M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$591K |
| 4 |
Goldman Sachs
New York
|
-$320K |
| 5 |
Russell Investments Group
London,
United Kingdom
|
-$172K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | +$43 | +2 | New |
|
|
CFGS
77
Concourse Financial Group Securities
Birmingham,
Alabama
| – | +$304 | +14 | New |
|
CASI Hedge Fund Activity: Q4 2020 in Review
73 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q4 2020, worth a combined $122M — up 105% from $59.6M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new CASI positions and 6 closed out — a net gain of 6 holders — while 30 added to existing stakes and 17 trimmed.
The largest buyer was Consonance Capital Management, adding an estimated $2.21M. The largest seller was Renaissance Technologies, cutting an estimated $1.15M.
- 73 institutional investors held CASI Pharmaceuticals (CASI) as of Q4 2020, up from 67 in Q3 2020.
- Funds reported $122M of CASI Pharmaceuticals stock for Q4 2020, up 105% quarter-over-quarter.
- 12 funds opened new CASI Pharmaceuticals positions in Q4 2020 and 6 closed out, a net change of +6 holders.
- The largest CASI Pharmaceuticals buyer in Q4 2020 was Consonance Capital Management, an estimated $2.21M added.
- The largest CASI Pharmaceuticals seller in Q4 2020 was Renaissance Technologies, an estimated $1.15M sold.
Based on aggregated 13F filings for Q4 2020.